NASDAQ:OPNTOpiant Pharmaceuticals Stock Price, Forecast & News

Opiant Pharmaceuticals' stock was trading at $10.85 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, OPNT stock has increased by 5.3% and is now trading at $11.42. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opiant Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Opiant Pharmaceuticals.

Opiant Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Opiant Pharmaceuticals.

Opiant Pharmaceuticals Inc (NASDAQ:OPNT) announced its quarterly earnings data on Tuesday, May, 12th. The technology company reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.19) by $0.21. The technology company earned $4.28 million during the quarter, compared to the consensus estimate of $4.63 million. Opiant Pharmaceuticals had a return on equity of 3.27% and a net margin of 29.58%. View Opiant Pharmaceuticals' earnings history.

1 brokerages have issued twelve-month price objectives for Opiant Pharmaceuticals' stock. Their forecasts range from $42.00 to $42.00. On average, they anticipate Opiant Pharmaceuticals' stock price to reach $42.00 in the next year. This suggests a possible upside of 267.8% from the stock's current price. View analysts' price targets for Opiant Pharmaceuticals.

News coverage about OPNT stock has been trending somewhat negative recently, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Opiant Pharmaceuticals earned a news impact score of -1.7 on InfoTrie's scale. They also assigned media stories about the technology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutOpiant Pharmaceuticals.

Opiant Pharmaceuticals saw a decrease in short interest in the month of April. As of April 30th, there was short interest totaling 3,200 shares, a decrease of 5.9% from the April 15th total of 3,400 shares. Based on an average daily trading volume, of 18,400 shares, the short-interest ratio is presently 0.2 days. Approximately 0.1% of the company's shares are sold short. View Opiant Pharmaceuticals' Current Options Chain.

Some companies that are related to Opiant Pharmaceuticals include Rubicon Minerals (RBYCF), Fission Uranium (FCUUF), Mountain Province Diamonds (MPVDF), Amerigo Resources (ARREF), Pacific Booker Minerals (PBMLF), Atlatsa Resources (ATLRF), Santa Fe Gold (SFEG), Bullfrog Gold (BFGC), Silver Bull Resources (SVBL), US Gold (USAU), Wealth Minerals (WMLLF), Avalon Advanced Materials (AVLNF), Quantum Materials (QTMM), Dakota Territory Resource (DTRC) and Westwater Resources (WWR). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Opiant Pharmaceuticals investors own include AcelRx Pharmaceuticals (ACRX), Cara Therapeutics (CARA), Synchrony Financial (SYF), Vodafone Group (VOD), Cyberark Software (CYBR), AT&T (T), Corbus Pharmaceuticals (CRBP), Cronos Group (CRON), Vodafone Group (VOD) and Agenus (AGEN).

Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT."

Opiant Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Stonepine Capital Management LLC (8.95%), Fondren Management LP (7.38%), BlackRock Inc. (0.49%), Mesirow Financial Investment Management Inc. (0.48%), Alambic Investment Management L.P. (0.36%) and Wedge Capital Management L L P NC (0.30%). Company insiders that own Opiant Pharmaceuticals stock include Ann L Macdougall, David D O'toole, Gabrielle Alison Silver, Michael Sinclair, Phil Skolnick and Roger Crystal. View institutional ownership trends for Opiant Pharmaceuticals.

OPNT stock was sold by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC, and BlackRock Inc.. Company insiders that have sold Opiant Pharmaceuticals company stock in the last year include Michael Sinclair, and Phil Skolnick. View insider buying and selling activity for Opiant Pharmaceuticals.

OPNT stock was bought by a variety of institutional investors in the last quarter, including Fondren Management LP, Stonepine Capital Management LLC, Mesirow Financial Investment Management Inc., Alambic Investment Management L.P., Acadian Asset Management LLC, Advisor Group Holdings Inc., and Morgan Stanley. Company insiders that have bought Opiant Pharmaceuticals stock in the last two years include Ann L Macdougall, David D O'toole, and Gabrielle Alison Silver. View insider buying and selling activity for Opiant Pharmaceuticals.

Shares of OPNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OPNT stock can currently be purchased for approximately $11.42.

Opiant Pharmaceuticals has a market capitalization of $48.65 million and generates $40.52 million in revenue each year. The technology company earns $11.59 million in net income (profit) each year or $0.20 on an earnings per share basis. Opiant Pharmaceuticals employs 16 workers across the globe.

The official website for Opiant Pharmaceuticals is www.opiant.com.

Opiant Pharmaceuticals' mailing address is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. The technology company can be reached via phone at 310-598-5410 or via email at [email protected]